Identification of a serum biomarker signature associated with metastatic prostate cancer

Venera Kuci Emruli, Leena Liljedahl, Ulrika Axelsson, Corinna Richter, Lisa Theorin, Anders Bjartell, Hans Lilja, Jenny Donovan , David Neal, Freddie C. Hamdy, Carl A. K. Borrebaeck

Research output: Contribution to journalArticle (Academic Journal)peer-review

1 Citation (Scopus)
59 Downloads (Pure)


Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.

Experimental design
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.

A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.

Conclusions and clinical relevance
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
Original languageEnglish
Article number2000025
Number of pages13
JournalProteomics - Clinical applications
Issue number2-3
Early online date13 Feb 2021
Publication statusPublished - 4 May 2021

Bibliographical note

Funding Information:
This study was supported by funding from Vinnova (UDI 2016‐00462) and CREATE Health Cancer Center at Lund University. Hans Lilja was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (MSKCC) [P30 CA008748], a SPORE grant in Prostate Cancer [P50‐CA92629], the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation, the Swedish Cancer Society (CAN 2017/559), and the Swedish Research Council (VR‐MH project no. 2016–02974). The ProtecT trial is funded by the UK National Institute for Health Research Health Technology Assessment Program (projects 96/20/06, 96/20/99, ) with the University of Oxford as sponsor. Department of Health disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health. Freddie Hamdy is supported in part by the National Institute for Health Research Oxford Biomedical Research Centre (Oxford NIHR BRC).

Publisher Copyright:
© 2021 The Authors. Proteomics – Clinical Applications published by Wiley-VCH GmbH


  • affinity proteomics
  • antibody microarrays
  • biomarkers
  • cancer
  • prostate cancer


Dive into the research topics of 'Identification of a serum biomarker signature associated with metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this